143 related articles for article (PubMed ID: 15317721)
21. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema.
Payne JF; Clark WL; Bruce BB; Wykoff CC; Brown DM; Menke BM; Iverson SM; Allen KF; Boyer DS;
Ophthalmology; 2018 Aug; 125(8):1304-1306. PubMed ID: 29729809
[No Abstract] [Full Text] [Related]
22. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
[TBL] [Abstract][Full Text] [Related]
23. Correlation analysis of fundus autofluorescence, spectral domain optical coherence tomography, and visual function in patients with diabetic macular oedema treated with intravitreal ziv-aflibercept.
Hernandez-Da Mota SE; Melo-Granados EAR; Fromow-Guerra J; Bejar-Cornejo F; Gallego-Pinazo R; Rodríguez-Ayala E
Eur J Ophthalmol; 2019 May; 29(3):271-277. PubMed ID: 30841748
[TBL] [Abstract][Full Text] [Related]
24. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.
Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM
Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955
[TBL] [Abstract][Full Text] [Related]
25. Diabetic macular oedema quantified with spectral-domain optical coherence tomography--evaluation of boundary line artefacts and the effect on retinal thickness.
Hodzic-Hadzibegovic D; Sander BA; Lund-Andersen H
Acta Ophthalmol; 2015 Feb; 93(1):74-82. PubMed ID: 25042850
[TBL] [Abstract][Full Text] [Related]
26. A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study).
Ramu J; Yang Y; Menon G; Bailey C; Narendran N; Bunce C; Quartilho A; Prevost AT; Hykin P; Sivaprasad S;
Eye (Lond); 2015 Dec; 29(12):1603-12. PubMed ID: 26493038
[TBL] [Abstract][Full Text] [Related]
27. Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema.
Shimura M; Yasuda K; Yasuda M; Nakazawa T
Retina; 2013 Apr; 33(4):740-7. PubMed ID: 23222391
[TBL] [Abstract][Full Text] [Related]
28. Visual outcome after intravitreal triamcinolone acetonide depends on optical coherence tomographic patterns in patients with diffuse diabetic macular edema.
Shimura M; Yasuda K; Nakazawa T; Hirano Y; Sakamoto T; Ogura Y; Shiono T
Retina; 2011 Apr; 31(4):748-54. PubMed ID: 21836404
[TBL] [Abstract][Full Text] [Related]
29. Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection.
Al Faran A; Mousa A; Al Shamsi H; Al Gaeed A; Ghazi NG
Retina; 2014 Jun; 34(6):1208-15. PubMed ID: 24368308
[TBL] [Abstract][Full Text] [Related]
30. Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study.
Brasil OF; Smith SD; Galor A; Lowder CY; Sears JE; Kaiser PK
Br J Ophthalmol; 2007 Jun; 91(6):761-5. PubMed ID: 17108013
[TBL] [Abstract][Full Text] [Related]
31. Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF.
Brito P; Costa J; Gomes N; Costa S; Correia-Pinto J; Silva R
J Diabetes Complications; 2018 Jul; 32(7):643-649. PubMed ID: 29843962
[TBL] [Abstract][Full Text] [Related]
32. Effects of fenofibric acid on diabetic macular edema: the MacuFen study.
Massin P; Peto T; Ansquer JC; Aubonnet P; MacuFEN Study Investigators FT
Ophthalmic Epidemiol; 2014 Oct; 21(5):307-17. PubMed ID: 25133794
[TBL] [Abstract][Full Text] [Related]
33. Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema.
Kikuchi Y; Odashima Y; Yoshikawa K; Oda T; Tanaka F; Oikawa H; Ishigaki Y; Asahi K
BMC Nephrol; 2022 Oct; 23(1):348. PubMed ID: 36309669
[TBL] [Abstract][Full Text] [Related]
34. Optical coherence tomographic pattern may predict visual outcome after intravitreal triamcinolone for diabetic macular edema.
Gibran SK; Khan K; Jungkim S; Cleary PE
Ophthalmology; 2007 May; 114(5):890-4. PubMed ID: 17467527
[TBL] [Abstract][Full Text] [Related]
35. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Kumar V; Ghosh B; Raina UK; Goel N
Am J Ophthalmol; 2008 Dec; 146(6):974; author reply 974-5. PubMed ID: 19027427
[No Abstract] [Full Text] [Related]
36. Is the effect of intravitreal triamcinolone acetonide on diabetic macular edema dose-dependent?
Šaric B; Šaric VB; Motušic R; Predovic J
Eur J Ophthalmol; 2014; 24(2):221-7. PubMed ID: 24030541
[TBL] [Abstract][Full Text] [Related]
37. Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.
Antoszyk AN; Tarnowski KW; Basu K; Ehrlich JS; Haskova Z
Ophthalmol Retina; 2020 Oct; 4(10):1034-1036. PubMed ID: 32512056
[No Abstract] [Full Text] [Related]
38. Role of optical coherence tomography imaging in treatment of diabetic macular oedema.
Sajid AR; Chong VH
QJM; 2023 Sep; 116(8):705-706. PubMed ID: 37195429
[No Abstract] [Full Text] [Related]
39. One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1171-1176. PubMed ID: 32452251
[TBL] [Abstract][Full Text] [Related]
40. Resolution of diabetic papillopathy after a single intravitreal injection of ranibizumab.
Willerslev A; Munch IC; Larsen M
Acta Ophthalmol; 2012 Aug; 90(5):e407-9. PubMed ID: 22268957
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
